Entera Bio Ltd. (ENTX) 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Entera Bio Ltd. for the fiscal year ended December 31, 2024. Entera is a clinical-stage biopharmaceutical company focused on developing first-in-class oral tablet formats of peptides and protein replacement therapies using its proprietary N-Tab™ platform. The company targets underserved chronic conditions, primarily osteoporosis and hypoparathyroidism, aiming to replace injectable treatments with oral alternatives.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $181,000 | $0 |
| Net Loss | $(9.54) million | $(8.89) million |
| Operating Loss | $(9.59) million | $(8.89) million |
| Research & Development Expenses | $4.50 million | $4.51 million |
| General & Administrative Expenses | $5.10 million | $4.43 million |
| Cash and Cash Equivalents (Dec 31, 2024) | $8.66 million | $11.02 million |
| Accumulated Deficit | $(113.93) million | $(104.39) million |
| Net Cash Used in Operating Activities | $(6.82) million | $(7.31) million |
Note: Revenue in 2024 was derived from a research services agreement. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $181,000 in revenue in 2024 from a research services agreement, compared to zero revenue in 2023.
- Expense Growth: General and Administrative (G&A) expenses increased by approximately 15% ($665,000) year-over-year, driven by higher compensation, intellectual property costs, and consultant fees. R&D expenses remained relatively flat.
- Liquidity Position: Cash and cash equivalents decreased by approximately $2.36 million during 2024. However, subsequent to year-end (March 2025), the company raised additional capital, bringing total cash to approximately $21 million.
- Going Concern: The independent auditor has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows, although management believes current resources (including subsequent financing) will fund operations into Q3 2026.
Guidance, Outlook, and Risks
Outlook and Guidance: Entera does not provide specific financial guidance. Management anticipates continuing to incur substantial losses as it advances its clinical programs. The company expects its cash resources (as of March 2025) to be sufficient to fund operations into the third quarter of 2026, excluding the initiation of the pivotal Phase 3 study for its lead candidate, EB613. Funding for the Phase 3 study will require additional capital, which may not be available on acceptable terms.
Key Developments:
- EB613 (Osteoporosis): The company is preparing for a Phase 3 registrational study pending FDA qualification of the SABRE BMD endpoint, expected in 2025. Phase 2 data met primary and secondary endpoints.
- EB612 (Hypoparathyroidism): Phase 1 data presented in June 2024 showed significant systemic exposure and sustainable pharmacodynamic effects with a new formulation.
- OPKO Collaboration: In March 2025, Entera entered a collaboration with OPKO Health for the development of an oral GLP-1/Glucagon dual agonist (OXM). Entera issued 3.69 million shares to OPKO for $8.0 million, which is escrowed to fund development costs.
Risks and Contingencies:
- Geopolitical Risk: The company's headquarters and R&D are in Israel. The ongoing Israel-Hamas war and regional conflicts pose risks to operations, workforce availability (military reserve duty), and supply chains, though management states impact has been immaterial to date.
- Regulatory Uncertainty: Success depends on the FDA qualifying the BMD endpoint as a surrogate for fractures, which is critical for the Phase 3 design of EB613.
- Capital Requirements: The company requires substantial additional funding to complete clinical trials and commercialization. Failure to secure funding could force delays or termination of programs.
- Intellectual Property: The company relies on patents and trade secrets; infringement claims or failure to secure protection could materially harm the business.
Investor Verification Checklist
- Cash Runway: Verify the exact timing of the $8.0 million OPKO funding receipt and confirm the updated cash runway beyond Q3 2026.
- Phase 3 Funding Gap: Assess the estimated cost to initiate the EB613 Phase 3 study and the likelihood of securing this specific funding given the "substantial doubt" going concern opinion.
- FDA SABRE Timeline: Monitor the FDA's decision timeline regarding the qualification of the BMD surrogate endpoint, as this is a binary catalyst for the lead program.
- Geopolitical Exposure: Review updates on the impact of the Israel conflict on employee availability and manufacturing supply chains.
- Dilution Risk: Evaluate the potential dilution from future equity offerings required to fund the Phase 3 trial and ongoing operations.